Navigation Links
La Jolla Institute scientist takes quest to conquer Type 1 diabetes to the next level

SAN DIEGO (January 23, 2012) La Jolla Institute scientist Matthias von Herrath, M.D., a world leader in basic research on type 1 diabetes, has long dreamed of seeing his discoveries translated into new therapies to better treat this serious and chronic disorder. Dr. von Herrath may soon get his chance as head of a new translational type 1 diabetes center to be opened in Seattle in 2012 by Novo Nordisk, a global healthcare company specializing in diabetes care. Dr. von Herrath will continue to lead his vibrant and renowned research program at the La Jolla Institute for Allergy & Immunology on a part-time basis.

"We are excited by the opportunities that this dual appointment will provide Dr. von Herrath to take his discoveries to the next level clinical development," said Mitchell Kronenberg, Ph.D., La Jolla Institute president & chief scientific officer. "As a nonprofit biomedical research institute, our mission is to find the molecular causes of diseases, with the hope that our discoveries will one day be translated into new and better therapies. This is an important step toward that goal."

Dr. Jacob Sten Petersen, Novo Nordisk corporate vice president, said the new translational center will be based on an innovative strategic concept to move early stage discovery projects rapidly from mouse models into small clinical exploration trials in type 1 diabetes patients. "The primary goal of this initiative is to find new, innovative ways to treat people with type 1 diabetes," he said, adding that the Center is planned to open this summer.

The company sought Dr. von Herrath to lead the Center due to his stellar record in type 1 diabetes research. "Dr. von Herrath is generally regarded as one of the top researchers in the world in type 1 diabetes," said Dr. Petersen. "He has made several key advances and is the kind of dedicated, talented researcher that can fuel true innovation in type 1 diabetes treatment." Dr. von Herrath is the recipient of the Juvenile Diabetes Research Foundation's prestigious Scholar Award and in 2008 received the Outstanding Scientific Achievement Award from the American Diabetes Association.

The Center will focus on the development of type 1 diabetes immunotherapies, an area where Dr. von Herrath has specialized expertise. "My dream has always been to see the most promising immune-based interventions translated into better treatments for patients with diabetes," he said. "As head of the translational center, I will have an opportunity to pursue this dream, as well as forge new public-private collaborations to access other novel research ideas for potential development into better treatment options for people with type 1 diabetes."

Dr. Kronenberg said Novo Nordisk has the kind of strong biopharmaceutical development infrastructure that is necessary to take discoveries from research laboratories, into human clinical trials, and, if successful, into approved drugs. "By establishing this relationship with Novo Nordisk, Dr. von Herrath is accelerating an important and complementary process that is strongly supported by this Institute; one that moves discoveries toward becoming treatments available to patients," he said. "We are pleased that Dr. von Herrath has entered into this exciting endeavor, while at the same time maintaining his laboratory and research efforts at our Institute. Clearly, this type of arrangement is a win-win for the scientific community and for patients."

Based in Denmark, Novo Nordisk has a longstanding history in type 1 diabetes treatment and markets several drugs for diabetes sufferers worldwide. Globally, about 6,000 people work on the company's research and development activities.


Contact: Bonnie Ward
La Jolla Institute for Allergy and Immunology

Related biology news :

1. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
2. La Jolla Institute discovers novel tumor suppressor
3. Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
4. La Jolla Institute scientist leads team which discovers important new player in diabetes onset
5. La Jolla Institute scientist Klaus Ley receives Malpighi award
6. La Jolla Institute validates Type 1 diabetes computer models predictive success through lab testing
7. La Jolla Institute-led team illuminates cell pathway key to insulin resistance in Type 2 diabetes
8. La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders
9. La Jolla Institute opens major RNAi center for identifying genetic triggers of disease
10. La Jolla Institute discovers previously unknown cell interaction key in immune system attacks
11. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
Post Your Comments:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: